Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19352234 | SUBSTITUTED HETEROCYCLES AND USES THEREOF | October 2025 | December 2025 | Allow | 2 | 0 | 0 | No | No |
| 18755447 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | June 2024 | December 2025 | Allow | 18 | 1 | 1 | No | No |
| 18657306 | DIMETHYLTRYPTAMINE ANALOGUES AS NITRIC OXIDE DELIVERY DRUGS | May 2024 | December 2025 | Allow | 19 | 1 | 0 | Yes | No |
| 18630760 | MACROCYCLIC COMPOUNDS AND USES THEREOF | April 2024 | December 2025 | Allow | 20 | 1 | 0 | No | No |
| 18605922 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | March 2024 | August 2025 | Abandon | 17 | 0 | 1 | No | No |
| 18421022 | PROCESS FOR THE PRODUCTION OF TETRAAMINOBIPHENOL MACROCYCLIC LIGANDS; AND NOVEL TETRAAMINOBIPHENOL MACROCYCLIC LIGANDS | January 2024 | August 2025 | Allow | 18 | 0 | 0 | No | No |
| 18416455 | DERIVATIVES OF SUBSTITUTED MORPHOLINES AND USES THEREOF | January 2024 | July 2024 | Allow | 6 | 1 | 0 | No | No |
| 18401832 | PROCESS FOR THE PREPARATION OF A PDE4 INHIBITOR | January 2024 | September 2025 | Allow | 21 | 2 | 1 | No | No |
| 18537481 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | December 2023 | July 2025 | Allow | 20 | 0 | 0 | No | No |
| 18535218 | BISPHOSPHONATE QUINOLONE CONJUGATES AND USES THEREOF | December 2023 | January 2026 | Allow | 25 | 1 | 0 | Yes | No |
| 18534285 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | December 2023 | July 2025 | Allow | 19 | 1 | 0 | No | No |
| 18524322 | N,N diethyl-N'phenylpiperazine alpha 7 and alpha 9 nicotinic acetylcholine receptor agonists and antagonists | November 2023 | March 2025 | Allow | 16 | 1 | 0 | No | No |
| 18523516 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | November 2023 | January 2025 | Allow | 14 | 0 | 0 | No | No |
| 18509658 | METHIONINE ADENOSYLTRANSFERASE 2a (MAT2A) INHIBITORS AND USES THEREOF | November 2023 | February 2024 | Allow | 3 | 0 | 0 | No | No |
| 18505940 | BRUTON'S TYROSINE KINASE INHIBITORS | November 2023 | July 2025 | Abandon | 21 | 1 | 0 | No | No |
| 18503556 | COMPOUNDS AND METHODS FOR TREATING CANCER | November 2023 | June 2025 | Allow | 19 | 1 | 1 | No | No |
| 18384790 | COMPOUNDS AND THEIR USES AS MIF INHIBITORS | October 2023 | July 2025 | Abandon | 20 | 0 | 1 | No | No |
| 18484588 | TOLL-LIKE RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USE | October 2023 | April 2025 | Allow | 18 | 1 | 0 | No | No |
| 18481173 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | October 2023 | February 2024 | Allow | 4 | 1 | 0 | No | No |
| 18460821 | NITROGEN-CONTAINING HETEROCYCLIC AMIDE COMPOUND AND PHARMACEUTICAL USE THEREOF | September 2023 | November 2024 | Allow | 14 | 0 | 0 | No | No |
| 18241636 | BRYOSTATIN COMPOUNDS AND METHODS OF PREPARING THE SAME | September 2023 | June 2025 | Allow | 21 | 1 | 0 | Yes | No |
| 18019452 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | September 2023 | April 2025 | Allow | 26 | 1 | 1 | Yes | No |
| 18237435 | NOVEL PROCESS FOR PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORS | August 2023 | June 2025 | Abandon | 21 | 1 | 0 | No | No |
| 18236001 | PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES | August 2023 | May 2025 | Abandon | 21 | 1 | 0 | No | No |
| 18355792 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | July 2023 | September 2024 | Allow | 14 | 0 | 0 | Yes | No |
| 18222679 | PROCESS FOR THE PRODUCTION OF 5-(4-((2S,5S)-5-(4-CHLOROBENZYL)-2-METHYL-MORPHOLINO)PIPERIDIN-1-YL)-1H-1,2,4-TRIAZOL-3-AMINE | July 2023 | February 2025 | Allow | 19 | 1 | 0 | No | No |
| 18334672 | THERAPEUTIC DENDRIMERS | June 2023 | March 2025 | Abandon | 21 | 1 | 0 | No | No |
| 18329092 | METHOD OF FIXATING CARBON DIOXIDE TO SUBSTITUTED OXAZOLIDINONES | June 2023 | January 2026 | Allow | 31 | 0 | 0 | No | No |
| 18039386 | MERGED SCAFFOLD TAF1 INHIBITORS | May 2023 | January 2026 | Allow | 31 | 0 | 0 | No | No |
| 18322844 | Chemical Compounds | May 2023 | August 2024 | Allow | 14 | 0 | 0 | No | No |
| 18144641 | BICYCLIC COMPOUNDS AS KINASE MODULATORS, METHODS AND USES THEREOF | May 2023 | November 2024 | Allow | 18 | 1 | 0 | No | No |
| 18144065 | COMBINATIONS OF 15-PGDH INHIBITORS WITH CORTICOSTEROIDS AND/OR TNF INHIBITORS AND USES THEREOF | May 2023 | September 2025 | Abandon | 28 | 1 | 1 | No | No |
| 18136517 | Charged Ion Channel Blockers and Methods for Use | April 2023 | February 2025 | Allow | 22 | 1 | 0 | Yes | No |
| 18302259 | Aminothiazole Compounds as Inhibitors of CTPS1 | April 2023 | August 2025 | Allow | 27 | 1 | 1 | No | No |
| 18302557 | PROCESS FOR PREPARING A COMPOUND USEFUL TO TREAT MYCOSES | April 2023 | November 2024 | Allow | 19 | 1 | 0 | No | No |
| 18134564 | PROCESS FOR THE PREPARATION OF 6-(CYCLOPROPANEAMIDO)-4-((2-METHOXY-3-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)AMINO)-N-(METHYL-D3)PYRIDAZINE-3-CARBOXAMIDE | April 2023 | January 2025 | Allow | 21 | 1 | 1 | No | No |
| 18300234 | COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS | April 2023 | January 2025 | Allow | 21 | 1 | 1 | Yes | No |
| 18248065 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | April 2023 | December 2025 | Allow | 33 | 0 | 0 | Yes | No |
| 18247939 | 6-METHOXY-3,4-DIHYDRO-1H-ISOQUINOLIN COMPOUNDS | April 2023 | August 2025 | Allow | 28 | 0 | 0 | Yes | No |
| 18295394 | CDK Inhibitors And Their Use As Pharmaceuticals | April 2023 | July 2025 | Allow | 28 | 2 | 1 | No | No |
| 18168322 | INHIBITORS OF PARG | February 2023 | October 2024 | Allow | 20 | 1 | 1 | Yes | No |
| 18152987 | PEPTIDE CONJUGATES OF MICROTUBULE-TARGETING AGENTS AS THERAPEUTICS | January 2023 | October 2024 | Allow | 21 | 1 | 0 | No | No |
| 18148672 | 4-(METHYLAMINOPHENOXY)PYRDIN-3-YL-BENZAMIDE DERIVATIVES FOR TREATING CANCER | December 2022 | November 2024 | Abandon | 22 | 1 | 0 | No | No |
| 18147499 | DIMETHYLTRYPTAMINE ANALOGUES AS NITRIC OXIDE DELIVERY DRUGS | December 2022 | February 2024 | Allow | 13 | 1 | 0 | No | No |
| 18146513 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS, AND METHODS | December 2022 | October 2024 | Abandon | 22 | 1 | 0 | No | No |
| 18087774 | TREATING SICKLE CELL DISEASE WITH A PYRUVATE KINASE R ACTIVATING COMPOUND | December 2022 | March 2024 | Allow | 14 | 0 | 0 | No | No |
| 18011460 | OXOPYRIDAZINYL-PHENYL-CARBONOHYDRAZONOYL DICYANIDE COMPOUND AND USE THEREOF | December 2022 | December 2025 | Allow | 36 | 1 | 0 | No | No |
| 18011459 | FUSED-HETEROCYCLYL-CARBONOHYDRAZONOYL DICYANIDE COMPOUNDS AND USE THEREOF | December 2022 | December 2025 | Allow | 35 | 1 | 0 | Yes | No |
| 18066389 | THERMALLY REACTIVE IMIDAZOLE-BASED LATENT CURING AGENT AND METHOD OF PREPARING THE SAME | December 2022 | February 2025 | Abandon | 26 | 2 | 1 | No | No |
| 18062356 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | December 2022 | June 2024 | Allow | 18 | 1 | 0 | No | No |
| 18075557 | HETEROCYCLIC ANTIVIRAL AGENTS | December 2022 | July 2024 | Allow | 19 | 1 | 0 | No | No |
| 17989393 | Compounds for the Treatment of Kinase-Dependent Disorders | November 2022 | August 2024 | Abandon | 21 | 1 | 0 | No | No |
| 18055874 | CHROMANE AMIDINE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | November 2022 | June 2023 | Allow | 7 | 0 | 0 | No | No |
| 17987208 | CRYSTALLINE N-METHYL TRYPTAMINE DERIVATIVES | November 2022 | December 2025 | Abandon | 37 | 0 | 1 | No | No |
| 17986325 | RADICAL COMPOUNDS AND METHODS OF USING THEREOF | November 2022 | January 2024 | Allow | 14 | 0 | 0 | Yes | No |
| 18054272 | OLAPARIB HYDROXYBENZOIC ACID COCRYSTALS AND THEIR PHARMACEUTICAL USE | November 2022 | March 2024 | Allow | 16 | 1 | 0 | No | No |
| 17983484 | ALKYNE-CONTAINING ANTIVIRAL AGENTS | November 2022 | August 2023 | Allow | 9 | 0 | 0 | No | No |
| 18051471 | SOLID FORMS OF FXR AGONISTS | October 2022 | June 2024 | Allow | 19 | 0 | 1 | Yes | No |
| 17962273 | Substituted Imidazo[4,5-c]pyridine Compounds and Compositions Thereof | October 2022 | July 2024 | Abandon | 22 | 1 | 0 | No | No |
| 17960586 | CONJOINT THERAPIES FOR IMMUNOMODULATION | October 2022 | April 2024 | Allow | 18 | 1 | 0 | No | No |
| 17951640 | PYRIDINE DERIVATIVES AND THEIR USE AS SODIUM CHANNEL ACTIVATORS | September 2022 | March 2024 | Allow | 18 | 1 | 0 | No | No |
| 17942928 | USE OF NEURONAL NITRIC OXIDE SYNTHASE INHIBITORS FOR IMMUNOTHERAPY IN MELANOMA PATIENTS | September 2022 | May 2024 | Allow | 20 | 1 | 0 | No | No |
| 17940617 | SUBSTITUTED MACROCYCLIC INDOLE DERIVATIVES | September 2022 | October 2023 | Allow | 13 | 0 | 0 | Yes | No |
| 17903735 | N,N diethyl-N'phenylpiperazine alpha 7 and alpha 9 nicotinic acetylcholine receptor agonists and antagonists | September 2022 | September 2023 | Allow | 20 | 1 | 0 | No | No |
| 17896626 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | August 2022 | September 2023 | Allow | 13 | 0 | 0 | Yes | No |
| 17820374 | SUBSTITUTED ENEOXINDOLES AND USES THEREOF | August 2022 | February 2024 | Allow | 18 | 1 | 0 | No | No |
| 17820271 | Aryl Sulfonyl (Hydroxy) Piperidines as CCR6 Inhibitors | August 2022 | October 2023 | Allow | 14 | 1 | 0 | Yes | No |
| 17879600 | METHODS OF MANUFACTURING BENZOQUINOLINE COMPOUNDS | August 2022 | April 2024 | Allow | 21 | 1 | 0 | Yes | No |
| 17815391 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | July 2022 | September 2023 | Allow | 14 | 0 | 0 | Yes | No |
| 17813382 | P38ALPHA MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS | July 2022 | December 2023 | Allow | 17 | 1 | 0 | No | No |
| 17607115 | TROLOX-PEPTIDE CONJUGATE AND USE THEREOF | July 2022 | November 2025 | Allow | 48 | 1 | 0 | No | No |
| 17844772 | Compounds and Methods for Treatment of Visceral Pain | June 2022 | October 2024 | Allow | 28 | 1 | 1 | Yes | No |
| 17807464 | TRICYCLIC PYRIDONES AND PYRIMIDONES | June 2022 | December 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17783810 | BICYCLIC HETEROCYCLE COMPOUNDS METHODS OF USE THEREOF FOR THE TREATMENT OF HERPES VIRUSES | June 2022 | August 2025 | Allow | 38 | 0 | 0 | No | No |
| 17834847 | QUINOLINE DERIVED SMALL MOLECULE INHIBITORS OF NICOTINAMIDE N-METHYLTRANSFERASE (NNMT) AND USES THEREOF | June 2022 | April 2024 | Allow | 22 | 2 | 0 | Yes | No |
| 17780903 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | May 2022 | August 2025 | Allow | 39 | 0 | 1 | Yes | No |
| 17664305 | TOLL-LIKE RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USE | May 2022 | July 2023 | Allow | 14 | 0 | 0 | No | No |
| 17743214 | BRUTON'S TYROSINE KINASE INHIBITORS | May 2022 | January 2024 | Abandon | 20 | 1 | 0 | No | No |
| 17743016 | Blue Phosphorescent Material, Production Method Thereof, and Photophysical Properties Thereof | May 2022 | November 2025 | Allow | 42 | 2 | 0 | No | No |
| 17738630 | PROCESS FOR THE PREPARATION OF A PDE4 INHIBITOR | May 2022 | October 2023 | Allow | 17 | 1 | 0 | No | No |
| 17774638 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF ISCHEMIA REPERFUSION INJURY AND INFECTION | May 2022 | November 2025 | Allow | 43 | 2 | 1 | No | No |
| 17734875 | COMBINATION THERAPY OF AXL INHIBITOR AND EGFR TYROSINE KINASE INHIBITOR | May 2022 | August 2023 | Allow | 15 | 1 | 0 | No | No |
| 17773490 | MODIFIED ZEOLITE CATALYST COMPOSITIONS AND METHODS OF USE | April 2022 | November 2025 | Allow | 43 | 1 | 1 | No | No |
| 17720007 | Process For The Preparation Of Highly Pure Salcaprozic Acid And Pharmaceutically Acceptable Salts Thereof | April 2022 | January 2023 | Allow | 9 | 0 | 0 | No | No |
| 17708296 | PROCESS FOR PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORS | March 2022 | May 2023 | Allow | 14 | 0 | 0 | No | No |
| 17699793 | Methods, Agents, and Compositions for the Treatment of Acute Myeloid Leukemia | March 2022 | January 2024 | Allow | 22 | 2 | 0 | No | No |
| 17698592 | DERIVATIVES OF SUBSTITUTED MORPHOLINES AND USES THEREOF | March 2022 | October 2023 | Allow | 19 | 1 | 0 | No | No |
| 17688822 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF | March 2022 | October 2023 | Allow | 20 | 1 | 0 | No | No |
| 17676942 | MACROCYCLIC COMPOUNDS AND USES THEREOF | February 2022 | January 2024 | Allow | 22 | 2 | 0 | No | No |
| 17670469 | THERAPEUTIC INHIBITION AFFINITY OF COPPER (II) COMPLEX AND THEIR DIAZENYL PYRIDINONE HETEROCYCLIC LIGANDS AGAINST SARS-COV2 | February 2022 | July 2023 | Allow | 17 | 1 | 0 | No | No |
| 17650732 | HPK1 ANTAGONISTS AND USES THEREOF | February 2022 | November 2024 | Allow | 33 | 5 | 0 | Yes | No |
| 17650387 | BAICALEIN ANALOGS FOR USE IN NEUROPROTECTION AND REGULATION OF IMMUNE REACTIVITY | February 2022 | September 2023 | Allow | 19 | 1 | 0 | No | No |
| 17585145 | SULFATE SALT OF THE FREE BASE OF N-[5-(AMINOSULFONYL)-4-METHYL-1,3-THIAZOL-2-YL]-N-METHYL-2-[4-(2-PYRIDINYL)-PHENYL]-ACETAMIDE, PHARMACEUTICAL FORMULATIONS, METHODS OF MANUFACTURE AND USES THEREOF | January 2022 | April 2024 | Allow | 27 | 2 | 0 | No | No |
| 17559546 | PHENYL PROPIONIC ACID DERIVATIVES AND USES THEREOF | December 2021 | February 2025 | Allow | 38 | 0 | 0 | Yes | No |
| 17596388 | OXO-PYRIDINE FUSION RING DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | December 2021 | October 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17532413 | 7-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME | November 2021 | October 2023 | Allow | 23 | 1 | 0 | No | No |
| 17532036 | ANTI-PARASITIC COMPOUNDS AND USES THEREOF | November 2021 | April 2024 | Allow | 29 | 1 | 1 | No | No |
| 17525778 | IRE1ALPHA INHIBITORS AND USES THEREOF | November 2021 | September 2023 | Allow | 22 | 1 | 0 | No | No |
| 17523652 | PHENYL PROPIONIC ACID DERIVATIVES AND USES THEREOF | November 2021 | April 2023 | Allow | 18 | 0 | 0 | Yes | No |
| 17519013 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | November 2021 | September 2023 | Allow | 23 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CARCANAGUE, DANIEL R.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 100.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner CARCANAGUE, DANIEL R works in Art Unit 1621 and has examined 179 patent applications in our dataset. With an allowance rate of 91.1%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 24 months.
Examiner CARCANAGUE, DANIEL R's allowance rate of 91.1% places them in the 75% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by CARCANAGUE, DANIEL R receive 1.31 office actions before reaching final disposition. This places the examiner in the 18% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by CARCANAGUE, DANIEL R is 24 months. This places the examiner in the 81% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.
Conducting an examiner interview provides a +11.1% benefit to allowance rate for applications examined by CARCANAGUE, DANIEL R. This interview benefit is in the 45% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 29.8% of applications are subsequently allowed. This success rate is in the 57% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 86.5% of cases where such amendments are filed. This entry rate is in the 97% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 86% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 66.7% are granted (fully or in part). This grant rate is in the 71% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.2% of allowed cases (in the 63% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.